MedTrace Logo

Neodent Implantable Devices of GM Line

NCT03812276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2023-02-10

No results posted yet for this study

Summary

Acqua GM (Grand Morse) Helix implants present an optimized implant design with adapted treatment protocol, allowing for treatment of patients with different bone qualities.

The objective of the study is to prospectively collect clinical data to confirm the long-term safety and clinical performance of Acqua GM Helix implants and GM prosthetic abutments in daily dental practice setting, by means of success and survival rates of these devices.

Devices will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (instructions for use). patients will be followed for 36 months after implant placement.

Conditions

  • Jaw, Edentulous
  • Jaw, Edentulous, Partially

Interventions

DEVICE

Dental Implants

Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).

Sponsors & Collaborators

  • Neodent

    lead INDUSTRY

Principal Investigators

  • Larissa Trojan, PhD · Neodent

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-02-14
Primary Completion
2023-01-10
Completion
2023-01-28
FDA Device
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03812276 on ClinicalTrials.gov